Showing 2699 results for "amyotrophic lateral sclerosis (ALS)"

BioElectron’s EPI-589 Shows Positive Results in ALS Patients in Phase 2a Trial

Investigational compound EPI-589 was found to be safe and well-tolerated, improved biomarkers of neuroinflammation, and showed signs of slowing disease progression in amyotrophic lateral sclerosis (ALS) patients, according to a completed Phase 2a clinical trial. BioElectron Technology Corporation’s EPI-589, or (R)-troloxamide quinone, is a 250 mg immediate-release, film-coated…

Parkinson’s Therapy Azilect Added to Rilutek May Delay Fast-progressing ALS, Phase 2 Trial Shows

Adding Azilect (rasagiline) — a medication already approved to treat Parkinson’s disease — to Rilutek (riluzole) may be able to slow the advancement of fast-progressing amyotrophic lateral sclerosis (ALS), a Phase 2 trial suggests. However, its positive safety results are being challenged by other physicians, who raise concerns that…